期刊文献+

恶性黑色素瘤的靶向治疗 被引量:3

Targeted therapy for malignant melanoma
原文传递
导出
摘要 目前恶性黑色素瘤(MM)主要的靶向治疗方法包括信号传导通路抑制剂、靶向凋亡、蛋白酶体抑制剂、抗血管生成治疗等。MM靶向治疗研究的发展方向是根据患者对靶向治疗敏感性的差异选择更加个体化的靶向治疗方法和技术。 Now, the main methods of targeted therapy for malignant melanoma (MM) include signal transduction pathway inhibitors, targeted apoptosis, proteasome inhibitors, antiangiogenic therapies. The devel- opment direction of the targeted therapy is to select more individualized methods and techniques according to the patients difference of sensitivity for targeted therapy.
出处 《国际肿瘤学杂志》 CAS 2009年第2期149-151,共3页 Journal of International Oncology
关键词 黑色素瘤 生物疗法 靶向治疗 临床分析 Melanoma Biological therapy
  • 相关文献

参考文献18

  • 1Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma : state of the art 2006. Melanoma Res, 2007, 17 ( 2 ) : 117-127.
  • 2Pratilas CA, Solit DB. Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials, 2007, 2(2) :121-154.
  • 3McDermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase Ⅱ study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol, 2008, 26(13) :2178-2185.
  • 4Margolin KA, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase Ⅱ trial of the California Cancer Consortium. Cancer, 2005, 104(5) :1045-1048.
  • 5Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 2004, 24(4) : 893-900.
  • 6Chin L. The genetics of malignant melanoma : Lessons from mouse and man. Nat Rev Cancer, 2003, 3(8): 559-570.
  • 7Kuzbicki LA, adowicz E, Chwirot BW. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions. Melanoma Res, 2006, 16 ( 5 ) :435-444.
  • 8Burdette- Radoux S, Tozer RG, Lohmann RC, et al. Phase Ⅱ trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated meta- static malignant melanoma. Invest New Drugs, 2004, 22 ( 3 ) : 315- 322.
  • 9Anurova OA, Likhvantseva VG, Vereshchagina MV. Study of a role of the expression of a transmembranous CDllT/C-Kit receptor in the progression of uveal melanomas. Vestn Oftalmol, 2007, 123 (5) :41 - 44.
  • 10Kim KB, Eton O, Davis DW. Phase Ⅱ trial of imatinib mesylate in patients with metastatic melanoma. BrJ Cancer, 2008, 99(5) :734- 740.

同被引文献29

  • 1李志琴,章静波.细胞周期调控与肿瘤(1)[J].癌症进展,2004,2(1):70-75. 被引量:20
  • 2牛艳洁,冯光丽,韩宝惠,陈岗.肺恶性黑色素瘤一例[J].上海医学,2005,28(6):535-536. 被引量:6
  • 3黄婵桃,陈卫国,贾铭,吴元魁,杨慧,周大菊.右肺原发性恶性黑色素瘤1例[J].中国医学影像技术,2007,23(1):158-158. 被引量:5
  • 4Apostolos D,Charalambos Z,Evangelia K,et al.Primary Malignant Melanoma of the lung:A case report[J].World J Surg Oncol,2003,1(1):26.
  • 5Wyman K,Kelley M,Puzanov I,et al.Phase Ⅱ study of erlotinib given daily for patients with metastatic melanoma[J].Journal of Clinical Oncology,2006,24(18):18002.
  • 6Wyman K,Spigel D,Puzanov I,et al.A multicenter phase study of erlotinib and bevacizumab in patients with metastatic melanoma[J].Journal of Clinical Oncology,2007,25(18):8539.
  • 7Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts [ J ]. Cancer Res, 2000, 60 ( 17 ) :4932-4938.
  • 8Tsunoda S, Nakamura T, Sakurai H, et al. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization [ J]. Cancer Sci, 2007, 98(4) : 541-548.
  • 9Cross M J, Claesson-Welsh L. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition [Jl. Trends Pharmacol Sei, 2001, 22(4): 201-207.
  • 10Demirkesen C, Btiytikpinarbagili N, Ramazanoglu R, et al. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: A comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibrohlastie growth factor [J]. Pathology, 2006, 38(2): 132-137.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部